TCMD · Tactile Systems Technology Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $329.52M | $292.98M | $274.42M | $246.78M | $208.06M | $187.13M |
| Cost of Revenue | $79.38M | $76.30M | $79.29M | $70.81M | $59.84M | $54.32M |
| Gross Profit | $250.15M | $216.69M | $195.13M | $175.98M | $148.21M | $132.81M |
| R&D | $8.48M | $8.83M | $7.82M | $7.09M | $5.66M | $5.26M |
| SG&A | $88.70M | $71.14M | $62.07M | $60.80M | $56.80M | $51.54M |
| Total Operating Expenses | $220.87M | $194.51M | $177.09M | $188.73M | $149.97M | $136.44M |
| D&A | $6.64M | $6.79M | $6.54M | $6.27M | $3.68M | $2.79M |
| Operating Income | $29.28M | $22.18M | $18.04M | ($12.76M) | ($1.76M) | ($3.63M) |
| Interest Expense | $1.04M | $2.08M | - | - | - | - |
| Income Tax | $12.25M | $6.53M | ($12.74M) | $2.39M | $9.52M | ($1.64M) |
| Net Income | $19.09M | $16.96M | $28.52M | ($17.87M) | ($11.81M) | ($620.0K) |
| EPS - Basic | $0.83 | $0.71 | $1.24 | ($0.89) | ($0.60) | ($0.03) |
| EPS - Diluted | $0.82 | $0.70 | $1.23 | ($0.89) | ($0.60) | ($0.03) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.45M | $94.37M | $61.03M | $21.93M | $28.23M | $47.85M |
| Accounts Receivable | $43.88M | $44.94M | $43.17M | $54.83M | $49.48M | $43.85M |
| Inventory | $14.03M | $18.67M | $22.53M | $23.12M | $19.22M | $18.56M |
| Accounts Payable | $4.97M | $5.65M | $6.66M | $9.98M | $5.02M | $4.20M |
| Current Assets | $165.17M | $177.56M | $145.29M | $119.76M | $113.55M | $123.61M |
| Total Assets | $273.94M | $297.92M | $281.44M | $255.00M | $244.27M | $174.09M |
| Current Liabilities | $40.96M | $40.70M | $41.06M | $64.33M | $34.46M | $26.71M |
| Long-term Debt | $0 | - | $16.80M | - | - | - |
| Total Liabilities | $55.04M | $81.33M | $87.80M | $133.60M | $116.04M | $49.34M |
| Stockholders' Equity | $218.90M | $216.60M | $193.64M | $121.40M | $128.23M | $124.75M |
| Retained Earnings | $54.94M | $35.85M | $18.89M | ($9.62M) | $8.24M | $20.06M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $42.81M | $40.66M | $35.85M | $5.21M | $2.63M | $2.79M |
| Investing Cash Flow | ($2.54M) | ($2.50M) | ($2.48M) | ($1.91M) | ($82.18M) | $20.18M |
| Financing Cash Flow | ($51.20M) | ($4.82M) | $5.73M | ($9.60M) | $59.93M | $2.11M |
| CapEx | $2.38M | $2.39M | $2.32M | $1.78M | $2.10M | $2.06M |
| Free Cash Flow | $40.43M | $38.26M | $33.53M | $3.43M | $528.0K | $735.0K |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.9% | 74.0% | 71.1% | 71.3% | 71.2% | 71.0% |
| Operating margin | 8.9% | 7.6% | 6.6% | -5.2% | -0.8% | -1.9% |
| EBITDA margin | 10.9% | 9.9% | 9.0% | -2.6% | 0.9% | -0.4% |
| Net margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | -0.3% |
| Free cash flow margin | 12.3% | 13.1% | 12.2% | 1.4% | 0.3% | 0.4% |
| FCF / Net income | 2.12 | 2.26 | 1.18 | -0.19 | -0.04 | -1.19 |
| R&D / Revenue | 2.6% | 3.0% | 2.9% | 2.9% | 2.7% | 2.8% |
| SG&A / Revenue | 26.9% | 24.3% | 22.6% | 24.6% | 27.3% | 27.5% |
| Effective tax rate | 39.1% | 27.8% | -80.8% | - | - | - |
| Return on assets | 7.0% | 5.7% | 10.1% | -7.0% | -4.8% | -0.4% |
| Return on equity | 8.7% | 7.8% | 14.7% | -14.7% | -9.2% | -0.5% |
| Return on invested capital | 8.1% | - | 8.6% | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.03 | 4.36 | 3.54 | 1.86 | 3.29 | 4.63 |
| Quick ratio | 3.69 | 3.90 | 2.99 | 1.50 | 2.74 | 3.93 |
| Cash ratio | 2.04 | 2.32 | 1.49 | 0.34 | 0.82 | 1.79 |
| Leverage | ||||||
| Debt / Equity | 0.00 | - | 0.09 | - | - | - |
| Debt / Assets | 0.00 | - | 0.06 | - | - | - |
| Debt / EBITDA | 0.00 | - | 0.68 | - | - | - |
| Interest coverage | 28.2x | 10.6x | - | - | - | - |
| Equity multiplier | 1.25 | 1.38 | 1.45 | 2.10 | 1.90 | 1.40 |
| Liabilities / Assets | 0.20 | 0.27 | 0.31 | 0.52 | 0.48 | 0.28 |
| Efficiency | ||||||
| Asset turnover | 1.20 | 0.98 | 0.98 | 0.97 | 0.85 | 1.07 |
| Inventory turnover | 5.66 | 4.09 | 3.52 | 3.06 | 3.11 | 2.93 |
| Days sales outstanding | 49d | 56d | 57d | 81d | 87d | 86d |
| Days inventory outstanding | 64d | 89d | 104d | 119d | 117d | 125d |
| Days payable outstanding | 23d | 27d | 31d | 51d | 31d | 28d |
| Cash conversion cycle | 90d | 118d | 130d | 149d | 173d | 182d |
| Valuation | ||||||
| P / E | 35.4x | 24.5x | 11.6x | - | - | - |
| P / B | 3.1x | 1.9x | 1.7x | 1.9x | 2.9x | 7.0x |
| P / S | 2.1x | 1.4x | 1.2x | 0.9x | 1.8x | 4.6x |
| EV / EBITDA | 16.5x | 11.0x | 11.7x | - | 180.8x | - |
| Growth | ||||||
| Revenue growth (YoY) | 12.5% | 6.8% | 11.2% | 18.6% | 11.2% | -1.2% |
| Revenue CAGR (3y) | 10.1% | 12.1% | 13.6% | 9.2% | 35.0% | 19.6% |
| Revenue CAGR (5y) | 12.0% | 9.1% | 26.6% | 17.7% | 19.7% | - |
| Gross profit growth (YoY) | 15.4% | 11.0% | 10.9% | 18.7% | 11.6% | -1.1% |
| Operating income growth (YoY) | 32.0% | 22.9% | - | -624.1% | 51.4% | - |
| Net income growth (YoY) | 12.5% | -40.5% | - | -51.3% | -1805.0% | - |
| EPS growth (YoY) | 17.1% | -43.1% | - | -48.3% | -1900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | 4.6% | 29.3% | - | - | - |
| FCF growth (YoY) | 5.7% | 14.1% | 877.9% | 549.4% | -28.2% | - |
| FCF CAGR (5y) | 122.9% | - | 47.4% | 0.8% | -39.0% | - |
| Book value growth (YoY) | 1.1% | 11.9% | 59.5% | -5.3% | 2.8% | 10.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$659.04M totalProduct$292.59M · 44.4%
Lymphedema Products$278.38M · 42.2%
Airway Clearance Products$51.14M · 7.8%
Rental Product Service$36.93M · 5.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.70
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TACTILE SYSTEMS TECHNOLOGY INC against the 5 most active filers in the same SIC group.